Molecular Templates Inc
(NAS:MTEM)
$
1.48
-0.035 (-2.31%)
Market Cap: 9.74 Mil
Enterprise Value: 8.71 Mil
PE Ratio: 0
PB Ratio: 1.37
GF Score: 54/100 - Molecular Templates Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 15, 2023
- G1 Therapeutics Inc, Molecular Templates Inc, Olema Pharmaceuticals Inc and Puma Biotechnology Inc at Cowen Health Care Conference- Panel TranscriptMar 07, 2023
- Molecular Templates Inc at Piper Sandler Healthcare Conference TranscriptDec 01, 2022
- Molecular Templates Inc at Evercore ISI HealthCONx Conference (Virtual) TranscriptNov 30, 2022
- Molecular Templates Inc To Present Interim Data and Host R&D Day at The Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting TranscriptNov 11, 2022
- Molecular Templates Inc To Discuss Unique Approach To Immuno-Oncology For Solid Tumors Call TranscriptApr 13, 2022
- Molecular Templates Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) TranscriptSep 20, 2021
- Molecular Templates Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 10, 2021
- Molecular Templates Inc To Discuss The Use of Egineer Toxin Bodies (EBTs) TranscriptSep 29, 2020
- Molecular Templates Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 17, 2020
- Molecular Templates Inc at UBS Global Healthcare Conference (Virtual) TranscriptMay 18, 2020
- Molecular Templates Inc R&D Day TranscriptNov 15, 2019
- Molecular Templates Inc at UBS Global Healthcare Conference TranscriptMay 20, 2019
Molecular Templates Inc at UBS Global Healthcare Conference Transcript
May 20, 2019 / 12:00PM GMT
Carter Lewis Gould
UBS Investment Bank, Research Division - Large Cap Biotech Analyst
Great. Good morning. My name is Carter Gould, senior analyst here at UBS covering biotech sector. We're going to kick things off this morning by introducing Molecular Templates. We have the CEO and Founder, Dr. Eric Poma, here. When we look, we have a number of, sort of, antibody-based companies or companies in the antibody space that come across our desk, but I would argue Molecular Templates is one of the definitely unique and novel platforms that we've seen in some time.
Questions & Answers
Carter Lewis Gould
UBS Investment Bank, Research Division - Large Cap Biotech Analyst
And so I guess maybe to kick things off, it would be helpful if, Eric, maybe you give us a little bit of background of technology and the company.
Eric E. Poma
Molecular Templates, Inc. - CEO, Chief Scientific Officer & Director
Sure. So the company was founded 10 years ago. Our goal was to really build a new mechanism of action in oncology.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)